[Lung Cancer Stem-like Cells and Drug Resistance]

Zhongguo Fei Ai Za Zhi. 2022 Feb 20;25(2):111-117. doi: 10.3779/j.issn.1009-3419.2022.102.02.
[Article in Chinese]

Abstract

Lung cancer remains the leading cause of cancer-related death world-wide. Therapy resistance and relapse are considered major reasons contributing to the poor survival rates of lung cancer. Accumulated evidences have demonstrated that a small subpopulation of stem-like cells existed within lung cancer tissues and cell lines, possessing the abilities of self-renewal, multipotent differentiation and unlimited proliferation. These lung cancer stem-like cells (LCSCs) can generate tumors with high effeciency in vivo, survive cytotoxic therapies, and eventually lead to therapy resistance and recurrence. In this review, we would like to present recent knowledges on LCSCs, including the origins where they come from, the molecular features to identify them, and key mechanisms for them to survive and develop resistance, in order to provide a better view for targeting them in future clinic. .

【中文题目:肺癌干性样细胞与耐药】 【中文摘要:肺癌是全球致死率最高的肿瘤,耐药和复发是肺癌致死率居高不下的关键原因之一。大量研究证据表明,在肺癌组织和细胞中存在一小群具有干性样特征的细胞,这群细胞被证实能够自我更新、多向分化和无限增殖,在体内可以高效成瘤,能在放疗和化疗中存活,最终引起肺癌的耐药和复发。本文着重针对肺癌干性样细胞的来源、分子生物学特征和鉴定方法以及广谱耐药机制进行综述,旨在为进一步研究其临床诊断和靶向策略提供依据。 】 【中文关键词:肺肿瘤;干性样细胞;耐药;靶向】.

Keywords: Drug resistance; Lung neoplasms; Stem-like cells; Therapy.

Publication types

  • Review

MeSH terms

  • Cell Line, Tumor
  • Drug Resistance
  • Drug Resistance, Neoplasm
  • Humans
  • Lung / pathology
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / metabolism
  • Neoplasm Recurrence, Local
  • Neoplastic Stem Cells / pathology

Grants and funding

本文受天津市医学重点学科(专科)建设项目资助